Barcelona Supercomputing Center and AstraZeneca signed a strategic collaboration agreement to apply AI, supercomputing, and advanced analytics to biomedical research.

Barcelona Supercomputing Center, or BSC, and AstraZeneca signed a strategic collaboration agreement announced on October 30. Its stated purpose is to accelerate the application of supercomputing, artificial intelligence, and advanced data analytics in biomedical research.

The collaboration will identify joint projects in biomedical research, innovative therapy development, and scientific acceleration. The announcement describes project identification and collaboration, not completed research findings or an approved therapy.

The supplied excerpt does not disclose a funding amount, committed compute allocation, named supercomputer, or project-delivery schedule. It therefore establishes the agreement’s research scope without supporting claims about GPU procurement, dedicated infrastructure deployment, or clinical outcomes.